News | May 01, 2025
Sigachi Industries signs MoU with Respilon Group
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
This approval authorizes the company to export Ibuprofen to the Chinese markets
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Subscribe To Our Newsletter & Stay Updated
